• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Opaleye Management Inc. bought $198,380 worth of shares (100,000 units at $1.98) (SEC Form 4)

    4/9/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Opaleye Management Inc.

    (Last) (First) (Middle)
    ONE BOSTON PLACE, 26TH FLOOR

    (Street)
    BOSTON MA 02108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CODEXIS, INC. [ CDXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 04/08/2025 P 100,000 A $1.9838(3) 9,465,000 I By Opaleye, L.P.(1)(4)
    Common Stock, par value $0.001 per share 250,000 I By Managed Account(2)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
    2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
    3. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9751 - $1.9899 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
    4. Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Opaleye Management Inc., By: /s/ James Silverman, President 04/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Codexis Appoints Cynthia Collins to Board of Directors

      REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

      4/1/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

      REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact

      2/6/25 4:05:30 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Appoints Christos Richards to Board of Directors

      REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies

      1/16/25 4:05:27 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $104,096 worth of shares (45,000 units at $2.31) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/2/25 4:05:14 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $55,915 worth of shares (25,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/29/25 4:05:11 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $298,772 worth of shares (140,000 units at $2.13) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/17/25 6:07:35 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $104,096 worth of shares (45,000 units at $2.31) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/2/25 4:05:14 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $55,915 worth of shares (25,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/29/25 4:05:11 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $298,772 worth of shares (140,000 units at $2.13) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/17/25 6:07:35 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Codexis Inc.

      SC 13G - CODEXIS, INC. (0001200375) (Subject)

      9/26/24 9:27:32 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Codexis Inc.

      SC 13G/A - CODEXIS, INC. (0001200375) (Subject)

      9/18/24 4:50:02 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by Codexis Inc.

      SC 13G - CODEXIS, INC. (0001200375) (Subject)

      7/12/24 4:15:13 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

      Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil

      5/7/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis to Report First Quarter 2025 Financial Results on May 14

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter

      4/30/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Announces Byron Dorgan to Retire from Board of Directors

      REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board. "On behalf of the entire Board of Directors, I want to express our appreciation for Byron's valuabl

      4/9/25 5:00:00 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Financials

    Live finance-specific insights

    See more
    • Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

      Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil

      5/7/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis to Report First Quarter 2025 Financial Results on May 14

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter

      4/30/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. "Throughout 2024, we continued to execute our strategy to advance the ECO Synthesis™ platform, a

      2/27/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Codexis downgraded by The Benchmark Company

      The Benchmark Company downgraded Codexis from Buy to Hold

      8/19/24 8:50:44 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Jefferies resumed coverage on Codexis with a new price target

      Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

      6/3/24 8:45:11 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Cantor Fitzgerald initiated coverage on Codexis with a new price target

      Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

      5/30/24 7:33:26 AM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Codexis Inc.

      DEFA14A - CODEXIS, INC. (0001200375) (Filer)

      4/24/25 4:05:44 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form DEF 14A filed by Codexis Inc.

      DEF 14A - CODEXIS, INC. (0001200375) (Filer)

      4/24/25 4:05:28 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CODEXIS, INC. (0001200375) (Filer)

      4/9/25 5:07:32 PM ET
      $CDXS
      Major Chemicals
      Industrials